These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 542805)

  • 21. [Increased effect of phenprocoumon (Marcumar) in nephrotic syndrome].
    Heni N; Völger R; Glogner P
    MMW Munch Med Wochenschr; 1980 Feb; 122(5):175-6. PubMed ID: 6767946
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs.
    Penning-van Beest FJ; van Meegen E; Rosendaal FR; Stricker BH
    Clin Pharmacol Ther; 2001 Jun; 69(6):451-7. PubMed ID: 11406743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism].
    Niermeijer MF
    Ned Tijdschr Geneeskd; 2006 Dec; 150(51):2839; author reply 2839-40. PubMed ID: 17216734
    [No Abstract]   [Full Text] [Related]  

  • 24. Interaction of allopurinol with phenprocoumon in man.
    Jähnchen E; Meinertz I; Gilfrich HJ
    Klin Wochenschr; 1977 Aug; 55(15):759-61. PubMed ID: 895010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Extent and quality of anti-coagulation treatment with coumarin derivatives by the Dutch Thrombosis Services].
    van Geest-Daalderop JH; Sturk A; Levi M; Adriaansen HJ
    Ned Tijdschr Geneeskd; 2004 Apr; 148(15):730-5. PubMed ID: 15119208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjustment of phenprocoumon dosage utilizing a pharmacokinetic model.
    Böhm K; Vogel G; Barthel W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):141-6. PubMed ID: 2459009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Liver injury caused by coumarin anticoagulants: experience of the IKS (Intercanton Monitoring Station) and the SANZ (Swiss Center for Drug Monitoring)].
    Ciorciaro C; Hartmann K; Stoller R; Kuhn M
    Schweiz Med Wochenschr; 1996 Dec; 126(49):2109-13. PubMed ID: 8999497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
    Rombouts EK; Rosendaal FR; van der Meer FJ
    Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon.
    Visser LE; Penning-van Beest FJ; Wilson JH; Vulto AG; Kasbergen AA; De Smet PA; Hofman A; Stricker BH
    Br J Clin Pharmacol; 2004 Apr; 57(4):522-4. PubMed ID: 15025752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cutaneous coumarin necrosis of the breast].
    Luderschmidt C; Gutschow K; Baumeister RG; Albrich W; Eiermann W
    Dtsch Med Wochenschr; 1983 Sep; 108(37):1399-402. PubMed ID: 6884225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of OTC drug noscapine and acenocoumarol and phenprocoumon.
    Lokhorst B; Rolfes L; Jessurun NT
    Br J Clin Pharmacol; 2019 May; 85(5):1041-1043. PubMed ID: 30809820
    [No Abstract]   [Full Text] [Related]  

  • 32. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
    Becker ML; Franken WP; Karapinar F; Verzijl-Zeegers R; Schalekamp T; van der Hoeven RT
    Eur J Clin Pharmacol; 2015 Dec; 71(12):1461-5. PubMed ID: 26400679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mischievous odds ratios.
    Steinsmith W
    PLoS Med; 2006 Apr; 3(4):e205; author reply 210. PubMed ID: 16626259
    [No Abstract]   [Full Text] [Related]  

  • 34. Statin use decreases coagulation in users of vitamin K antagonists.
    van Rein N; Biedermann JS; Bonafacio SM; Kruip MJ; van der Meer FJ; Lijfering WM
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1441-1447. PubMed ID: 27709253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk.
    Reitsma PH; van der Heijden JF; Groot AP; Rosendaal FR; Büller HR
    PLoS Med; 2005 Oct; 2(10):e312. PubMed ID: 16201835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement of fibrinopeptide A in patients treated with phenprocoumon.
    Harenberg J; Haas R; Zimmermann R
    Thromb Haemost; 1981 Jun; 45(3):282-4. PubMed ID: 7281107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of naproxen on the thrombocyte bleeding time and on the anticoagulant treatment with phenprocoumon].
    Angelkort B
    Fortschr Med; 1978 Jun; 96(23):1249-52. PubMed ID: 658877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of lung tumour colony reduction caused by coumarin anticoagulation.
    Hilgard P; Maat B
    Eur J Cancer (1965); 1979 Feb; 15(2):183-7. PubMed ID: 436894
    [No Abstract]   [Full Text] [Related]  

  • 39. Prognosis of prophylactic anticoagulant treatment in ischaemic stroke.
    Gallhofer B; Ladurner G; Lechner H
    Eur Neurol; 1979; 18(3):145-8. PubMed ID: 477686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study of the clinical effect of acenocoumarol (Sintrom) and phenprocoumon (Marcoumar) in myocardial infarction and angina pectoris.
    Fekkes N; de Jonge H; Veltkamp JJ; Bieger R; Loeliger EA
    Acta Med Scand; 1971 Dec; 190(6):535-40. PubMed ID: 5149098
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.